nanotech investing Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes
nanotech investing Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
nanotech investing Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
nanotech investing Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate
nanotech investing Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate
nanotech investing Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
nanotech investing Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
nanotech investing Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
nanotech investing Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
nanotech investing Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine Candidate
nanotech investing Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Heliostar Metals to Present at the Precious Metals & Critical Minerals Virtual Investor Conference October 14
Precious Metals & Critical Minerals Virtual Investor Conference Agenda Announced for October 13th - 15th
